PT Royal Prima Tbk (PRIM) Fair Value & Analysis
Healthcare · ID · Market cap 253B IDR
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 46.55 IDR to 1,251 IDR (+2,588.2%) since Jun 23, 2026. Share price +6.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 55.70 IDR – 99.68 IDR · fair‑value band 938.51 IDR – 1,564 IDR · the 86.00 IDR price screens below the 1,251 IDR fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PT Royal Prima Tbk (PRIM) currently trades at 86.00 IDR, while our model-based Fair Value estimate is 1,251 IDR — implying the stock looks roughly 1,355.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, PT Royal Prima Tbk generated revenue of 330B IDR at a net margin of -5.9%. Revenue declined 11.1% year over year. It earns a return on equity of -2.1%. The balance sheet holds a net cash position of 14.5B IDR. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PT Royal Prima Tbk engages in providing hospital services and drugs in Indonesia. The company operates its hospitals under the Royal Prima Medan, Royal Prima Jambi, and RSU Royal Prima Marelan names. The company also provides health services, such as inpatient and outpatient medical services, including specialist and sub-specialist care. In addition, the company offers orthopaedic, eye, neurology, internal medicine, obstetrics and gynaecology, heart, lung, Ent-kl, urology. Further, it provides other services, including general surgery, surgical oncology, plastic surgery, pediatric surgery, neurosurgery, digestive surgery, dermatologist and venereologist, psychiatric, dental polyclinic, oral surgery, vascular surgery, kidney and hypertension, endocrine metabolic diabetes. The company was founded in 2013 and is based in Jakarta, Indonesia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Royal Prima Tbk reported revenue of 339B IDR in FY2025 versus 600B IDR in FY2021, a compound −13.3%/yr. Reported net income was −21.8B IDR in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Tenet Healthcare Corporation THC | $164.77 | $280.85 | +70% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Royal Prima Tbk (PRIM) undervalued?
What is the fair value of PRIM?
What is the quality score of PRIM?
What is the revenue of PT Royal Prima Tbk (PRIM)?
What is the net profit margin of PRIM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.